Sodium Chloride New Zealand - English - Medsafe (Medicines Safety Authority)

sodium chloride

baxter healthcare ltd - sodium chloride 0.45% - solution for infusion - 0.45 % - active: sodium chloride 0.45% - hypotonic sodium chloride (0.45%) intravenous infusion is mainly used as a hydrating agent solution.

Sodium Chloride New Zealand - English - Medsafe (Medicines Safety Authority)

sodium chloride

baxter healthcare ltd - sodium chloride 3% - solution for infusion - 3 % - active: sodium chloride 3% - hypertonic sodium chloride (3%) intravenous infusion is used in the management of severe sodium chloride depletion when electrolyte restoration is required.

Sodium Chloride 0.9% Freeflex New Zealand - English - Medsafe (Medicines Safety Authority)

sodium chloride 0.9% freeflex

fresenius kabi new zealand limited - sodium chloride 9 g/l;  ;  ;  ;  ;   - solution for infusion - 0.9 % - active: sodium chloride 9 g/l           excipient: hydrochloric acid sodium hydroxide water for injection - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Sodium Chloride 0.45% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride 0.45% w/v solution for infusion

baxter healthcare limited - sodium chloride - solution for infusion - 0.45 percent weight/volume - electrolyte solutions; sodium chloride

Sodium Chloride 0.3 % w/v and Glucose 3.3% w/v Solution for Infusion BP Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride 0.3 % w/v and glucose 3.3% w/v solution for infusion bp

baxter healthcare limited - sodium chloride; glucose monohydrate - solution for infusion - 0.3 3.3 percent weight/volume - salt solutions; sodium chloride

Sodium Chloride 0.45 % w/v and Glucose 2.5% w/v Solution for Infusion BP Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride 0.45 % w/v and glucose 2.5% w/v solution for infusion bp

baxter healthcare limited - sodium chloride; sodium chloride; glucose monohydrate; glucose monohydrate - solution for infusion - 0.45 2.5 percent weight/volume - salt solutions; sodium chloride

Sodium Chloride 0.9 % w/v and Glucose 5% w/v Solution for Infusion BP (Viaflo container) Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride 0.9 % w/v and glucose 5% w/v solution for infusion bp (viaflo container)

baxter healthcare limited - sodium chloride; sodium chloride; glucose monohydrate; glucose monohydrate - solution for infusion - 0.9/5 %w/v percent weight/volume - salt solutions; sodium chloride

0.9% w/v Sodium Chloride Injection Malta - English - Medicines Authority

0.9% w/v sodium chloride injection

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - sodium chloride - solution for injection - sodium chloride 0.9 % (w/v) - all other non-therapeutic products

Baxter 0.45% Sodium Chloride and 5% Glucose Intravenous Infusion 1000 mL bag (AHB6028) Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 0.45% sodium chloride and 5% glucose intravenous infusion 1000 ml bag (ahb6028)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 4.5 g/l - injection - excipient ingredients: water for injections; hydrochloric acid - sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

SODIUM PHENYLACETATE AND SODIUM BENZOATE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium phenylacetate and sodium benzoate injection, solution, concentrate

mylan institutional llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. available data with sodium phenylacetate and sodium benzoate injection use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. g